Treatment Algorithms: Claims Data Analysis – Neuropsychiatric Therapies in Alzheimer’s Disease (US) | 2024
In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments for the neuropsychiatric symptoms of AD (e.g., Axsome’s Auvelity, Karuna / BMS’s KarXT). Psychosis and agitation can cause significant distress for AD patients and their caregivers and may contribute to nursing home placement. This study examines the class- and drug-level prescribing patterns for key neuropsychiatric therapies—antipsychotics, mood stabilizers, anxiolytics, and benzodiazepines—in patients diagnosed with AD to understand today’s treatment landscape and patient journey. These data will help developers of new and emerging options optimize the uptake and competitive positioning of their agents.
Questions Answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AD? What are the quarterly trends in prescribing among recently treated and newly diagnosed AD patients?
- How has Lundbeck / Otsuka’s Rexulti been integrated into the treatment algorithm, and what is its source of business?
- What percentage of AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AD patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Rexulti, Nuplazid, other antipsychotics (e.g., quetiapine), anxiolytics, benzodiazepines, mood stabilizers
Key analysis provided:
- Brand / therapy use across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key Feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
